NetScientific's mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people's lives and society. NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand. NetScientific’s investment model identifies late-stage translational research projects developing cutting-edge technologies in its disease focus areas. NetScientific then builds on accredited research, the previous stages of which have already been funded by academic institutions, governments and science foundations, to take the projects to the point of commercialisation. NetScientific is an active investor providing extensive management support. This can involve the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.
Show more
TypePublic
HQLondon, GB
Size (employees)23 (est)
Websitenetscientific.net
Netscientific is headquartered in London, GB
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Netscientific

Richard Sykes

Richard Sykes

Chairman
Francois Martelet

Francois Martelet

CEO
Barry Wilson

Barry Wilson

Non-Executive Director
Stephen Smith

Stephen Smith

Non-Executive Director
Ian Postlethwaite

Ian Postlethwaite

Chief Financial Officer & Company Secretary
Show more

Netscientific Office Locations

Netscientific has an office in London
London, (HQ)
30 Saint Mary Axe - Swiss Re 30 St Mary Axe
Show all (1)
Report incorrect company information

Netscientific Financials and Metrics

Netscientific Revenue

Netscientific's revenue was reported to be £386 k in FY, 2017
GBP

Revenue (FY, 2017)

386.0k

Gross profit (FY, 2017)

141.0k

Gross profit margin (FY, 2017), %

36.5%

Net income (FY, 2017)

(9.4m)

EBITDA (FY, 2017)

(10.4m)

EBIT (FY, 2017)

(10.6m)

Cash (31-Dec-2017)

6.9m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

16.0k177.7k21.0k518.0k386.0k

Revenue growth, %

274%559%

Cost of goods sold

6.0k255.0k245.0k

Gross profit

15.0k263.0k141.0k
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

410.8k25.5m16.9m23.2m9.5m6.9m

Accounts Receivable

260.057.3k37.0k109.0k115.0k

Inventories

86.0k

Current Assets

632.4k25.9m17.7m23.8m11.0m8.0m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(1.5m)(4.3m)(6.2m)(10.4m)(12.4m)(9.4m)

Cash From Operating Activities

(1.2m)(3.7m)(6.6m)(10.6m)(12.8m)(10.6m)

Cash From Financing Activities

861.5k28.9m190.0k17.2m70.0k7.5m

Net Change in Cash

(393.3k)25.1m(8.8m)6.2m(14.4m)(2.2m)
GBPY, 2017

Revenue/Employee

16.8k

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Netscientific Online and Social Media Presence

Embed Graph
Report incorrect company information

Netscientific Blogs

Form 8 (OPD) – NetScientific (Offeree)

The post Form 8 (OPD) – NetScientific (Offeree) appeared first on NetScientific.

Amendment to Executive Director Service Terms

The post Amendment to Executive Director Service Terms appeared first on NetScientific.

Announcement of Strategic Review

The post Announcement of Strategic Review appeared first on NetScientific.

PDS Biotechnology Enters into Merger Agreement with Edge Therapeutics to Form NASDAQ-Listed Clinical-Stage Cancer Immunotherapy Company

Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer Growing product pipeline utilising Versamune®, a novel, versatile, multi-functional platform Phase 1/2 clinical data on lead product candidate PDS0101 suggest…

Vortex Biosciences paves the way forward in CTC enumeration by introducing impedance measurements

London, UK – 08 November 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, has presented a study that demonstrates the feasibility of combining its technology with impedanc…

Vortex Biosciences and STRATEC GmbH announce global partnership to scale-up manufacturing for liquid biopsy platform

London, UK – 1 November 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, has entered into a global manufacturing agreement with STRATEC Consumables GmbH (“STRATEC”) to pro…
Show more

Netscientific Company Life and Culture

Report incorrect company information

Netscientific Frequently Asked Questions

  • Who are Netscientific key executives?

    Netscientific's key executives are Richard Sykes, Francois Martelet and Barry Wilson.

  • How many employees does Netscientific have?

    Netscientific has 23 employees.

  • What is Netscientific revenue?

    Latest Netscientific annual revenue is £386 k.

  • What is Netscientific revenue per employee?

    Latest Netscientific revenue per employee is £16.8 k.

  • Who are Netscientific competitors?

    Competitors of Netscientific include Bio-Reference Laboratories, Onco.com and American Vision Partners.

  • Where is Netscientific headquarters?

    Netscientific headquarters is located at 30 Saint Mary Axe - Swiss Re 30 St Mary Axe, London.

  • Where are Netscientific offices?

    Netscientific has an office in London.

  • How many offices does Netscientific have?

    Netscientific has 1 office.